Skip to main content
. 2022 Oct 23;13:6308. doi: 10.1038/s41467-022-34064-4

Fig. 9. LAT2 depletion sensitizes osteosarcoma to doxorubicin treatment.

Fig. 9

a–d Mice were treated with saline or doxorubicin (DOX) every other day after shCtrl or shLAT2 HOS tumors grew for 14 days. a Representative immunohistochemical images stained with F4/80, CD86, or CD47 antibodies in serial sections of tumors on day 22. Scale bar, 150 μm. b Statistical analyses of IHC quantification results for samples depicted in (a) (n = 5 mice per group). c Measurement of tumor growth in mice (n = 5 mice per group). Tumor volume was measured at the indicated time points. d Flow cytometric analysis of MHC-II, iNOS, CD86, Arginase 1, and CD206 expression in CD45+ CD11b+ F4/80+ macrophages in tumors on day 17 (n = 5 mice per group). e Volumes of tumors generated by shCtrl HOS cells or shLAT2 HOS cells after treatment as indicated (n = 5 mice per group). DOX, doxorubicin. Data are shown as the mean ± SD. ns not significant. *P < 0.05, **P < 0.01, ***P < 0.001, one-way ANOVA (b, d) or two-way ANOVA (c, e). The experiment was performed three times with similar results (a–e). See the Source Data file for the exact P values. Source data are provided as a Source Data file.